Compare Citius Pharmaceuticals Inc (CTXR) vs Pfizer Inc (PFE) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.

The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.